EverImmune raised €5.3M in a Series A round in Nov 2021. The company is based in Villejuif, France. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
